Quercetin 500 mg daily × Reduced MRI liver fat over 12 weeks — Evidence Check

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionSelected 12-week MRI outcome and original valuesRequired	Preserve the subclaim C and statistically positive surrogate note for reduced MRI liver fat over 12 weeks. Parent C with 54 points and original axes are parent-verdict context. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. The subclaim lacks score, status and axes; do not fill them with parent values. Do not create a new grade/effect or certification of clinical outcomes. Content review remains incomplete.	Selected existing question, grade/note, parent context and presence of score/status/axes	Connect the original question to additional materials in proposed update research; no new investigation, calculation or trial is performed now.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionParticipants with nonalcoholic fatty liver diseaseRequired	Preserve the original population of 41 participants with nonalcoholic fatty liver disease. Do not generalize to all fatty liver/liver diseases or other populations. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Detailed eligibility, age/baseline liver fat, weight/metabolic/comorbid conditions and sequence-specific characteristics are unverified. Content review remains incomplete.	Disease, recruitment/eligibility, baseline risk and arm/period characteristics	Propose follow-up research on population conditions and applicability; no new investigation, calculation or trial is performed now.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionQuercetin 500 mg and formulationRequired	Preserve quercetin 500 mg daily as the original study condition. Do not turn this into effects of every polyphenol/food or other products. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Raw material/manufacturing, product/batch, detailed composition, actual use/adherence and supply are unverified. Do not create intake instructions, conversions or product recommendations. Content review remains incomplete.	Specific study product, formulation/ingredients/batch and exposure	Propose follow-up research distinguishing formulation from result attribution; no new investigation, calculation or trial is performed now.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionPlacebo and crossover comparisonRequired	Preserve the original randomized double-blind placebo-controlled crossover design. Do not use two periods from the same participants as independent trials/participants. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Placebo identity/matching, sequence/period-specific exposure/adherence, concomitant conditions and actual deviations are unverified. Content review remains incomplete.	Actual placebo, sensory matching and conditions in each period	Propose follow-up research on comparator conditions and period-specific comparison definitions; no new investigation, calculation or trial is performed now.
5	Partly verified	Full text not readStored summary read	N05 · Evidence condition12 weeks and four-week washoutRequired	Preserve the original account of 12 weeks of quercetin or placebo followed by crossover after a 4-week washout. Do not sum or convert a new total duration/exposure. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Individual period starts/completion, washout adherence, subsequent return to baseline, actual assessment windows and stopping are unverified. Content review remains incomplete.	Intervention/measurement periods, washout and actual sequence	Propose follow-up research on time/carryover and observed results; no new investigation, calculation or trial is performed now.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionRandomized sequence and concealmentRequired	Preserve the randomized crossover trial and 41 randomized participants as recorded. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Sequence-specific denominators, generation/concealment, blocking/stratification, access/changes and actual implementation documents are unread. A design label alone does not certify absence of bias. Content review remains incomplete.	Crossover allocation sequence, generation/concealment and actual procedures	Propose follow-up research on allocation and period-specific population relationships; no new investigation, calculation or trial is performed now.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionMasking and MRI assessmentRequired	Preserve the double-blind design. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Actual masking of participants/researchers, MRI measurement/readers and analysts, maintenance/unmasking and imaging/region-of-interest standards are unverified. Content review remains incomplete.	Role-specific masking, measurement/image assessment and analysis procedures	Propose follow-up research on measurement/assessment bias and MRI results; no new investigation, calculation or trial is performed now.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionMRI-PDFF and the 12-week measureRequired	The original account describes MRI-PDFF intrahepatic lipid as an imaging surrogate and the 12-week primary outcome. It is distinct from cirrhosis, hospitalization and death. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Measurement/regions of interest, actual visits/repeats, baseline/final/period-specific comparison definitions and arm-specific observations are unverified. Content review remains incomplete.	Definition, units/measurement and timing of the intrahepatic-lipid measure	Propose follow-up research distinguishing imaging measures from other outcomes; no new investigation, calculation or trial is performed now.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionQuercetin-period baseline and final valuesRequired	Preserve quercetin-period 11.5%±6.4 to 9.6%±5.8 exactly. The manuscript’s approximate −1.9 percentage points is an existing historical reported/explanatory value, not a calculation performed now. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Arm/sequence, period-baseline/final observations, the type of ± quantity, models/adjustment and individual values are unverified. Do not calculate new changes, response rates or CIs. Content review remains incomplete.	Periods/populations, dispersion and distinction from change in original MRI values	Propose follow-up research on final values/change and period-specific analysis definitions; no new investigation, calculation or trial is performed now.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionPlacebo change and unitsRequired	Preserve the original placebo-period change of −0.1%±2.6. Keep the Korean concise summary’s %p wording in the whole original summary; do not arbitrarily correct units or create new final values/between-treatment differences. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Placebo-period baseline/final values, exact change definitions/units, the type of ± quantity, observed denominators/models and period matching are unverified. Content review remains incomplete.	Placebo-period change/final values, original units and estimands	Propose follow-up research distinguishing original estimands/units and comparison relationships; no new investigation, calculation or trial is performed now.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionP=.013 and adjusted P=.028Required	Preserve between-treatment P=.013 and multiplicity-adjusted P=.028 exactly. Do not calculate/certify new risk ratios/response rates, exact effects/CIs or clinical success. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Period/sequence, within-person correlation, adjustment/multiplicity methods, test lists and original estimates/outputs are unread. Content review remains incomplete.	Original test for the selected comparison, multiplicity/models and precision	Propose follow-up research on tests/multiplicity and uncertainty; no new investigation, calculation or trial is performed now.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionBetween-treatment CI and historical checking scopeRequired	Preserve the original statement that a between-treatment 95% CI was absent within the historically checked abstract/public-result-table scope. Only the preserved summary is read now; do not extend this to absence from the whole paper. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Original estimates/outputs, whole text/supplements and current CI/analysis data are unread. Do not create a new CI from original ± values, P values or sample sizes. Content review remains incomplete.	Precision and abstract/public-table checking versus current reading scope	Propose update research distinguishing precision data from materials actually read; no new investigation, calculation or trial is performed now.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionPrespecified important MRI thresholdRequired	Preserve the original statement that no minimum clinically important MRI-PDFF reduction threshold was declared. Do not promote statistical positivity to long-term clinical outcomes or confirmatory success. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Prespecified criteria, power/plans, correspondence to clinical measures and exact estimates/CIs are unverified. Content review remains incomplete.	Prespecified minimum clinically important difference and interpretation/success definitions	Propose research distinguishing statistical results from important differences/clinical meaning; no new investigation, calculation or trial is performed now.
14	Partly verified	Full text not readStored summary read	N14 · Evidence condition41 to 36: completion and analysisRequired	Preserve 41 randomized and 36 completed exactly. Do not calculate/declare new missing counts/rates, summed periods or a completer-only ITT population. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Sequence/period-specific completion, endpoint observations, withdrawal/missingness reasons, actual analysis populations and sensitivity analyses are unverified. Content review remains incomplete.	Randomized/completed participants, period-specific observations/analysis and missingness	Propose follow-up research on selected populations and missing-data assumptions; no new investigation, calculation or trial is performed now.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionITT and crossover modelRequired	Preserve the original account that ITT results were reported. Do not fill this in as verified MRI observations/denominators in every period for all 41 participants or a particular imputation model. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. MRI ITT denominators, within-person correlation, period/sequence, missing-data models, sensitivity analyses and actual original analyses are unread. Content review remains incomplete.	Actual ITT/allocation and period/sequence/within-person comparison definitions	Propose follow-up research on allocation/period, missing-data assumptions and estimation; no new investigation, calculation or trial is performed now.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionWashout, carryover and period effectsRequired	Preserve the original design of crossover after a 4-week washout. Do not treat the two periods as different participants or independent replication. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Return to baseline, carryover/sequence/period effects, tests/interactions, actual analyses and exposure adherence are unverified. Content review remains incomplete.	Carryover/sequence, period-specific baselines and analytical handling	Propose research distinguishing carryover/period effects from same-participant outcomes; no new investigation, calculation or trial is performed now.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionWeight change and correlationRequired	Preserve the original weight change of −1.5±2.6 kg during quercetin versus −0.2±1.8 kg during placebo and its correlation with liver-fat reduction. Direct hepatic and weight-mediated effects were not separated. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Correlation estimates, timing/populations, models/mediation analyses, concomitant activity/diet and original individual data are unverified. Do not calculate a new direct hepatic effect. Content review remains incomplete.	Separate weight/liver-fat measures and causal/mediation relationships	Propose follow-up research distinguishing weight/exposure from result attribution; no new investigation, calculation or trial is performed now.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionNull liver-enzyme and other secondary outcomesRequired	Preserve the original account that liver enzymes and other secondary endpoints were not significant. Do not reuse MRI positivity as benefits for liver enzymes or every clinical outcome. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Each measure/time point, denominator, value/estimate/CI, multiplicity and hierarchy are unverified. Do not turn nonsignificance into an exactly zero effect or equivalence. Content review remains incomplete.	Definitions/hierarchy of other endpoints, original results and the selected measure	Propose research on other measures, discordance and uncertainty; no new investigation, calculation or trial is performed now.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionConcomitant exposure, adherence and subsequent careRequired	Preserve the original scope of the specific quercetin/placebo crossover. S01	Information currently needed is unverified in the preserved summary. Diet/activity, weight management, drugs/supplements, actual intake/stopping/crossover and exposure in each period are unverified. Do not create new weight/diet/exercise, treatment or intake instructions. Content review remains incomplete.	Arm/period-specific activity/diet, drugs/products and actual exposure	Propose research on concomitant exposure and result attribution; no new investigation, calculation or trial is performed now.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionChiCTR and prespecified plansRequired	Preserve the original registration-field value ChiCTR2100047904. A registration number alone does not verify prespecification, original plans or CIs/criteria now. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Registration history, protocol/SAP, recruitment/measurement/analysis timing, multiplicity and amendments are unread. Content review remains incomplete.	Registration identity, plans/changes and correspondence to reports	Propose research connecting prespecified plans to result reporting; no new investigation, calculation or trial is performed now.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionFunding-agency names and unverified scopeRequired	Preserve the original funding/Korean-English account that a separate joint funding-agency name was not identified in the public text. Do not turn this into no funding or independence certification. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Actual providers/contracts, research/analysis/writing/publication roles and complete disclosures are unread now. Content review remains incomplete.	Funders, roles and the scope of the public text	Propose update research on historical checking scope and current materials; no new investigation, calculation or trial is performed now.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionManufacturer, product and analysis disclosuresRequired	The original account states that commercial-manufacturer funding, free products and outsourced analysis were not disclosed in the public text. Do not convert non-disclosure into no support or verification of all independence. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Manufacturing/supply, individual support, writing/publication fees and actual complete original disclosures are unread. Content review remains incomplete.	Individual records of commercial funding/products and analysis/writing/publication support	Propose research distinguishing gaps in individual disclosures/support; no new investigation, calculation or trial is performed now.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionInstitutional affiliations and COI declarationsRequired	Preserve the original account of Army Medical University/Xinqiao Hospital affiliations and a no-competing-interests declaration. Institutional affiliation does not certify funding or current independence. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Staff/contributions, timing of relationships/employment, equity/other COIs and detailed disclosures are unread. Content review remains incomplete.	Distinguish author affiliations/employment from contributions/interests	Propose research on declarations and author/institutional roles; no new investigation, calculation or trial is performed now.
24	Partly verified	Full text not readStored summary read	N24 · Harm-information gaps supplementing the efficacy tableSafety measures and rare harmsSupplementary	Preserve the original account that significant between-treatment differences in routine blood and other safety measures and intervention-related adverse events were not reported, together with the limitation that 41 participants are too few to evaluate rare harms. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Arm/period-specific harm denominators/events, collection/stopping/relatedness/missingness and long-term/vulnerable populations are unverified. Do not turn non-reporting/nonsignificance into zero harms or safety certification. Content review remains incomplete.	Harm collection/definitions, populations/periods and original reporting scope	Propose research on harm-reporting scope and rare/long-term outcomes; no new investigation, calculation or trial is performed now.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionRelationships within the same trial across periods/reportsRequired	Do not sum the single Li 2024/ChiCTR trial, 41 participants/36 completers, two periods/measurement times or MRI/weight/liver enzymes/sibling sheets as new independent trials/participants. Original R1/I2 are historical axes. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. External correspondence of same-participant periods/endpoints, unique populations/follow-up reports and independent replication under matching conditions has not been checked. Do not invent follow-up reports. Content review remains incomplete.	Distinguish reports/trials/participants, crossover/measures and independent replication	Propose research on same-data/period relationships and separate replication; no new investigation, calculation or trial is performed now.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionClinical outcomes and other formulations/durationsRequired	MRI positivity is not evidence of improved cirrhosis, hospitalization or death. Do not extend the specific 500 mg/12-week result to every polyphenol or other formulations/populations/long-term effects. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical outcomes, post-treatment durability, other doses/populations/periods and harms are unverified. Do not create treatment/intake methods. Content review remains incomplete.	Distinguish selected MRI results from actual clinical outcomes/outside populations	Propose research distinguishing imaging from clinical outcomes and selected conditions; no new investigation, calculation or trial is performed now.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionOriginal axes, Korean/English text, dates and correctionsRequired	The whole preserved summary retains subclaim C/note, parent C with 54 points/Good, B/S/R1/I2/E+/B1, unrecorded precision, three false flags, empty override reasons, Korean/English text, 2026-08-26 and empty corrections/deliberation. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Historical cross-check/abstract/public-table/full-text checking accounts are not current external reading/review or newly fulfilled conditions. Do not fill absent subclaim score/status/axes or absent parent classification keys. Content review remains incomplete.	Distinguish subclaim/parent values, original evidence date/corrections and history	Propose update research on source-material changes and production versions; no new investigation, calculation or trial is performed now.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionSummary reading and externally unread materialsRequired	The preserved summary was read for production, and the Li 2024/PMID 39032786 citation/URL is linked. Paper/registration/protocol/SAP/disclosures remain unread, with no access attempted. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Original URLs/registration and historical accounts do not raise current acquisition/reading/review status; external links/clicks have not been checked. Content review remains incomplete.	Actual reading for each material, citations/URLs and gaps in additional materials	Propose scoped update research based on materials actually acquired; no new investigation, calculation or trial is performed now.

No items match your search or filter.

28 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Single crossover trial in nonalcoholic fatty liver disease: 41 randomized and 36 completed. Detailed eligibility/baseline, sequence/period populations, MRI observations/denominators and exclusions/missingness are unverified. Do not sum two periods/measures from the same participants as independent trials/participants.
Ingredient, formulation and route: Quercetin 500 mg daily as the original study condition. Product/batch, raw material/formulation, actual adherence/stopping and concomitant exposure are unverified. Do not convert this to effects of other polyphenols/foods, products or doses, or create new intake/treatment instructions.
Dose: Preserve the original design of 12 weeks of quercetin or placebo followed by crossover after a 4-week washout. Actual sequence/period-specific exposure/completion, carryover/return to baseline and visit windows are unverified. Do not sum/convert new total duration/exposure.
Comparator: Randomized double-blind placebo-controlled crossover comparison. Placebo/sensory matching, sequence allocation/concealment, MRI-assessor/analyst masking, concomitant diet/activity and original crossover models/missingness/adherence are unverified. Do not inherit original design/ITT accounts as current procedural verification.
Measured outcome: Selected statistically positive 12-week MRI-PDFF intrahepatic-lipid surrogate. Preserve quercetin-period 11.5%±6.4 to 9.6%±5.8, the original approximate −1.9 percentage points, placebo-period change −0.1%±2.6, P=.013 and multiplicity-adjusted P=.028. Original %/%p wording is retained separately in the preserved original; do not create new changes/between-treatment differences, ratios/CIs or unit corrections. The type of ± quantity, within-person/period models, observed/ITT denominators and exact estimates are unverified. Distinguish the historical checking scope for between-treatment CIs and prespecified minimum MRI thresholds.
Duration: The MRI primary outcome is at 12 weeks; distinguish the 4-week washout/crossover from actual measurement in each period. Post-treatment durability, overall long-term/clinical/harm outcomes are unverified. Do not calculate a new total follow-up duration from original periods.
Questions outside this scope: New effect/change/response-rate/CI calculations or arbitrary %/%p corrections from MRI baseline/final values, placebo change, original approximate −1.9 percentage points/P values/± quantities and sample sizes; Summing two crossover periods/the same participants as new independent trials/participants, or deriving hypothetical total duration/exposure from 12 weeks/4 weeks; Filling an ITT account with unverified observed denominators, imputation models or an all-completer population; Turning weight correlation and MRI benefit into confirmation of direct hepatic causation/separated mediation, or calculating new direct effects; Reusing MRI/liver-enzyme/other secondary outcomes as improved cirrhosis/hospitalization/death, or exactly zero clinical effects/equivalence; Inheriting historical CI/funding checking in abstracts/public tables/full text as current whole external-document reading/review; Turning undisclosed manufacturer support, institutional affiliations/no-COI declarations and original I2 into absence of each support item/current independence verification; Turning original safety non-reporting/nonsignificance and rare-harm limitations into zero harms or treatment-safety certification; Creating currently absent clinical original reports/registration/follow-up materials or invented citations/values; Inheriting parent scores/axes and historical cross-checking as subclaim scores/current review/external reading; New calculations, hypothetical values, effects/CIs, grades, independence certification or product-intake/diet/activity/testing/treatment implementation guidance

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Li N et al. 2024

PubMed

Material type: Randomized double-blind placebo-controlled crossover trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: 11.5%±6.4 to 9.6%±5.8 versus placebo change −0.1%±2.6; P=0.013, adjusted P=0.028. Original grade C with 54 points: in the 41-participant double-blind crossover trial, quercetin-period liver fat changed from 11.5%±6.4 to 9.6%±5.8, an approximate 1.9-percentage-point reduction, versus placebo change −0.1%±2.6; between-treatment P=0.013 and multiplicity-adjusted P=0.028. The original approximate −1.9 percentage points already appears in the preserved manuscript as a historical reported/explanatory value, not a new calculation. Distinguish original absence of a CI/minimum important threshold, period/unit/weight-mediation gaps and currently unread external materials.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Li 2024/ChiCTR2100047904 is a single double-blind placebo-controlled crossover trial in nonalcoholic fatty liver disease, with 41 randomized and 36 completed. Distinguish original quercetin 500 mg/day, 12-week intervention and crossover after a 4-week washout from unverified actual sequence/period/exposure and ITT/observation/missing-data models. Quercetin-period MRI 11.5%±6.4 to 9.6%±5.8, original approximate −1.9 percentage points, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are original surrogate results, not new calculations. Do not arbitrarily correct %/%p wording; retain gaps in the type of ± quantity, between-treatment CI/important difference and original period/within-person estimates. Weight changes −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction/unseparated direct hepatic effects, nonsignificant liver enzymes/other secondary outcomes and untested clinical cirrhosis/hospitalization/death are distinct outcomes. Do not sum the same participants/arms, crossover periods, MRI/weight/liver enzymes, citations or sibling sheets as new independent trials/participants. Do not create follow-up reports/clinical effects or inherit original R1/I2 and historical abstract/public-table/full-text checking accounts as current review/external reading. Report/material-slot counts are not unique clinical trial/participant/independent-replication totals; no new sums or independence certification are performed.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only stored-summary and bibliographic content was used for production. External material verification/review is not complete.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 Li 2024/ChiCTR2100047904 is a single double-blind placebo-controlled crossover trial in nonalcoholic fatty liver disease, with 41 randomized and 36 completed. Distinguish original quercetin 500 mg/day, 12-week intervention and crossover after a 4-week washout from unverified actual sequence/period/exposure and ITT/observation/missing-data models. Quercetin-period MRI 11.5%±6.4 to 9.6%±5.8, original approximate −1.9 percentage points, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are original surrogate results, not new calculations. Do not arbitrarily correct %/%p wording; retain gaps in the type of ± quantity, between-treatment CI/important difference and original period/within-person estimates. Weight changes −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction/unseparated direct hepatic effects, nonsignificant liver enzymes/other secondary outcomes and untested clinical cirrhosis/hospitalization/death are distinct outcomes. Do not sum the same participants/arms, crossover periods, MRI/weight/liver enzymes, citations or sibling sheets as new independent trials/participants. Do not create follow-up reports/clinical effects or inherit original R1/I2 and historical abstract/public-table/full-text checking accounts as current review/external reading. Report/material-slot counts are not unique clinical trial/participant/independent-replication totals; no new sums or independence certification are performed.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Selected 12-week MRI outcome and original values

Required materials and conditions: Selected existing question, grade/note, parent context and presence of score/status/axes
Conditions for verification: Selected existing question, grade/note, parent context and presence of score/status/axes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Selected existing question, grade/note, parent context and presence of score/status/axes to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N02 · Participants with nonalcoholic fatty liver disease

Required materials and conditions: Disease, recruitment/eligibility, baseline risk and arm/period characteristics
Conditions for verification: Disease, recruitment/eligibility, baseline risk and arm/period characteristics requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Disease, recruitment/eligibility, baseline risk and arm/period characteristics to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N03 · Quercetin 500 mg and formulation

Required materials and conditions: Specific study product, formulation/ingredients/batch and exposure
Conditions for verification: Specific study product, formulation/ingredients/batch and exposure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Specific study product, formulation/ingredients/batch and exposure to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N04 · Placebo and crossover comparison

Required materials and conditions: Actual placebo, sensory matching and conditions in each period
Conditions for verification: Actual placebo, sensory matching and conditions in each period requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Actual placebo, sensory matching and conditions in each period to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application

N05 · 12 weeks and four-week washout

Required materials and conditions: Intervention/measurement periods, washout and actual sequence
Conditions for verification: Intervention/measurement periods, washout and actual sequence requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Intervention/measurement periods, washout and actual sequence to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

N06 · Randomized sequence and concealment

Required materials and conditions: Crossover allocation sequence, generation/concealment and actual procedures
Conditions for verification: Crossover allocation sequence, generation/concealment and actual procedures requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Crossover allocation sequence, generation/concealment and actual procedures to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 §8.1–8.2.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M08 §8.2.2, M15 §15.3.1; custom application

N07 · Masking and MRI assessment

Required materials and conditions: Role-specific masking, measurement/image assessment and analysis procedures
Conditions for verification: Role-specific masking, measurement/image assessment and analysis procedures requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Role-specific masking, measurement/image assessment and analysis procedures to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design

N08 · MRI-PDFF and the 12-week measure

Required materials and conditions: Definition, units/measurement and timing of the intrahepatic-lipid measure
Conditions for verification: Definition, units/measurement and timing of the intrahepatic-lipid measure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Definition, units/measurement and timing of the intrahepatic-lipid measure to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M03 §3.2.4; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary

N09 · Quercetin-period baseline and final values

Required materials and conditions: Periods/populations, dispersion and distinction from change in original MRI values
Conditions for verification: Periods/populations, dispersion and distinction from change in original MRI values requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Periods/populations, dispersion and distinction from change in original MRI values to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N10 · Placebo change and units

Required materials and conditions: Placebo-period change/final values, original units and estimands
Conditions for verification: Placebo-period change/final values, original units and estimands requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Placebo-period change/final values, original units and estimands to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N11 · P=.013 and adjusted P=.028

Required materials and conditions: Original test for the selected comparison, multiplicity/models and precision
Conditions for verification: Original test for the selected comparison, multiplicity/models and precision requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Original test for the selected comparison, multiplicity/models and precision to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N12 · Between-treatment CI and historical checking scope

Required materials and conditions: Precision and abstract/public-table checking versus current reading scope
Conditions for verification: Precision and abstract/public-table checking versus current reading scope requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Precision and abstract/public-table checking versus current reading scope to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N13 · Prespecified important MRI threshold

Required materials and conditions: Prespecified minimum clinically important difference and interpretation/success definitions
Conditions for verification: Prespecified minimum clinically important difference and interpretation/success definitions requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Prespecified minimum clinically important difference and interpretation/success definitions to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary

N14 · 41 to 36: completion and analysis

Required materials and conditions: Randomized/completed participants, period-specific observations/analysis and missingness
Conditions for verification: Randomized/completed participants, period-specific observations/analysis and missingness requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Randomized/completed participants, period-specific observations/analysis and missingness to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application

N15 · ITT and crossover model

Required materials and conditions: Actual ITT/allocation and period/sequence/within-person comparison definitions
Conditions for verification: Actual ITT/allocation and period/sequence/within-person comparison definitions requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Actual ITT/allocation and period/sequence/within-person comparison definitions to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M15 §15.3.1–15.3.3; custom application

N16 · Washout, carryover and period effects

Required materials and conditions: Carryover/sequence, period-specific baselines and analytical handling
Conditions for verification: Carryover/sequence, period-specific baselines and analytical handling requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Carryover/sequence, period-specific baselines and analytical handling to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N17 · Weight change and correlation

Required materials and conditions: Separate weight/liver-fat measures and causal/mediation relationships
Conditions for verification: Separate weight/liver-fat measures and causal/mediation relationships requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Separate weight/liver-fat measures and causal/mediation relationships to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.4; custom extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design

N18 · Null liver-enzyme and other secondary outcomes

Required materials and conditions: Definitions/hierarchy of other endpoints, original results and the selected measure
Conditions for verification: Definitions/hierarchy of other endpoints, original results and the selected measure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Definitions/hierarchy of other endpoints, original results and the selected measure to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M04 §4.6.3; custom application; M15 §15.3.1–15.3.3; custom application

N19 · Concomitant exposure, adherence and subsequent care

Required materials and conditions: Arm/period-specific activity/diet, drugs/products and actual exposure
Conditions for verification: Arm/period-specific activity/diet, drugs/products and actual exposure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Arm/period-specific activity/diet, drugs/products and actual exposure to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

N20 · ChiCTR and prespecified plans

Required materials and conditions: Registration identity, plans/changes and correspondence to reports
Conditions for verification: Registration identity, plans/changes and correspondence to reports requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Registration identity, plans/changes and correspondence to reports to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N21 · Funding-agency names and unverified scope

Required materials and conditions: Funders, roles and the scope of the public text
Conditions for verification: Funders, roles and the scope of the public text requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Funders, roles and the scope of the public text to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N22 · Manufacturer, product and analysis disclosures

Required materials and conditions: Individual records of commercial funding/products and analysis/writing/publication support
Conditions for verification: Individual records of commercial funding/products and analysis/writing/publication support requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Individual records of commercial funding/products and analysis/writing/publication support to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

N23 · Institutional affiliations and COI declarations

Required materials and conditions: Distinguish author affiliations/employment from contributions/interests
Conditions for verification: Distinguish author affiliations/employment from contributions/interests requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Distinguish author affiliations/employment from contributions/interests to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N24 · Safety measures and rare harms

Required materials and conditions: Harm collection/definitions, populations/periods and original reporting scope
Conditions for verification: Harm collection/definitions, populations/periods and original reporting scope requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Supplement gaps in safety materials for the selected subclaim. Do not judge safety from MRI/clinical results or parent safety wording, or create harm-incidence estimates/new use instructions.
Why this condition is needed: Distinguish Harm collection/definitions, populations/periods and original reporting scope to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are custom design; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4, M04 §4.6.3; custom application; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4; custom application

N25 · Relationships within the same trial across periods/reports

Required materials and conditions: Distinguish reports/trials/participants, crossover/measures and independent replication
Conditions for verification: Distinguish reports/trials/participants, crossover/measures and independent replication requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Distinguish reports/trials/participants, crossover/measures and independent replication to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N26 · Clinical outcomes and other formulations/durations

Required materials and conditions: Distinguish selected MRI results from actual clinical outcomes/outside populations
Conditions for verification: Distinguish selected MRI results from actual clinical outcomes/outside populations requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Distinguish selected MRI results from actual clinical outcomes/outside populations to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4; custom extension boundary; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design

N27 · Original axes, Korean/English text, dates and corrections

Required materials and conditions: Distinguish subclaim/parent values, original evidence date/corrections and history
Conditions for verification: Distinguish subclaim/parent values, original evidence date/corrections and history requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Distinguish subclaim/parent values, original evidence date/corrections and history to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

N28 · Summary reading and externally unread materials

Required materials and conditions: Actual reading for each material, citations/URLs and gaps in additional materials
Conditions for verification: Actual reading for each material, citations/URLs and gaps in additional materials requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: Distinguish Actual reading for each material, citations/URLs and gaps in additional materials to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review remains incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-12 · Public page/material version 1.0

Public reader pages and material were prepared from the existing 28 items. No new clinical searches, verification-state changes or scoring were performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Selected 12-week MRI outcome and original values

Current findings: Preserve the subclaim C and statistically positive surrogate note for reduced MRI liver fat over 12 weeks. Parent C with 54 points and original axes are parent-verdict context.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. The subclaim lacks score, status and axes; do not fill them with parent values. Do not create a new grade/effect or certification of clinical outcomes. Content review remains incomplete.
Reason for missing information: The subclaim lacks score, status and axes; do not fill them with parent values. Do not create a new grade/effect or certification of clinical outcomes.
Required materials and conditions: Selected existing question, grade/note, parent context and presence of score/status/axes
Materials to obtain first: Data distinguishing the selected row from the original parent verdict
Further research: Connect the original question to additional materials in proposed update research; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Selected existing question, grade/note, parent context and presence of score/status/axes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Selected existing question, grade/note, parent context and presence of score/status/axes to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N02 · Participants with nonalcoholic fatty liver disease

Current findings: Preserve the original population of 41 participants with nonalcoholic fatty liver disease. Do not generalize to all fatty liver/liver diseases or other populations.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Detailed eligibility, age/baseline liver fat, weight/metabolic/comorbid conditions and sequence-specific characteristics are unverified. Content review remains incomplete.
Reason for missing information: Detailed eligibility, age/baseline liver fat, weight/metabolic/comorbid conditions and sequence-specific characteristics are unverified.
Required materials and conditions: Disease, recruitment/eligibility, baseline risk and arm/period characteristics
Materials to obtain first: Recruitment/eligibility, baseline and sequence/period-specific participant data
Further research: Propose follow-up research on population conditions and applicability; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Disease, recruitment/eligibility, baseline risk and arm/period characteristics requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Disease, recruitment/eligibility, baseline risk and arm/period characteristics to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N03 · Quercetin 500 mg and formulation

Current findings: Preserve quercetin 500 mg daily as the original study condition. Do not turn this into effects of every polyphenol/food or other products.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Raw material/manufacturing, product/batch, detailed composition, actual use/adherence and supply are unverified. Do not create intake instructions, conversions or product recommendations. Content review remains incomplete.
Reason for missing information: Raw material/manufacturing, product/batch, detailed composition, actual use/adherence and supply are unverified. Do not create intake instructions, conversions or product recommendations.
Required materials and conditions: Specific study product, formulation/ingredients/batch and exposure
Materials to obtain first: Product/batch, composition, supply and actual exposure data
Further research: Propose follow-up research distinguishing formulation from result attribution; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Specific study product, formulation/ingredients/batch and exposure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Specific study product, formulation/ingredients/batch and exposure to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N04 · Placebo and crossover comparison

Current findings: Preserve the original randomized double-blind placebo-controlled crossover design. Do not use two periods from the same participants as independent trials/participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Placebo identity/matching, sequence/period-specific exposure/adherence, concomitant conditions and actual deviations are unverified. Content review remains incomplete.
Reason for missing information: Placebo identity/matching, sequence/period-specific exposure/adherence, concomitant conditions and actual deviations are unverified.
Required materials and conditions: Actual placebo, sensory matching and conditions in each period
Materials to obtain first: Placebo/matching, period-specific exposure and adherence/deviation data
Further research: Propose follow-up research on comparator conditions and period-specific comparison definitions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual placebo, sensory matching and conditions in each period requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Actual placebo, sensory matching and conditions in each period to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application

Related sources S01

N05 · 12 weeks and four-week washout

Current findings: Preserve the original account of 12 weeks of quercetin or placebo followed by crossover after a 4-week washout. Do not sum or convert a new total duration/exposure.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Individual period starts/completion, washout adherence, subsequent return to baseline, actual assessment windows and stopping are unverified. Content review remains incomplete.
Reason for missing information: Individual period starts/completion, washout adherence, subsequent return to baseline, actual assessment windows and stopping are unverified.
Required materials and conditions: Intervention/measurement periods, washout and actual sequence
Materials to obtain first: Sequence/period, washout and individual exposure/measurement data
Further research: Propose follow-up research on time/carryover and observed results; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Intervention/measurement periods, washout and actual sequence requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Intervention/measurement periods, washout and actual sequence to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

Related sources S01

N06 · Randomized sequence and concealment

Current findings: Preserve the randomized crossover trial and 41 randomized participants as recorded.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Sequence-specific denominators, generation/concealment, blocking/stratification, access/changes and actual implementation documents are unread. A design label alone does not certify absence of bias. Content review remains incomplete.
Reason for missing information: Sequence-specific denominators, generation/concealment, blocking/stratification, access/changes and actual implementation documents are unread. A design label alone does not certify absence of bias.
Required materials and conditions: Crossover allocation sequence, generation/concealment and actual procedures
Materials to obtain first: Original sequence-allocation, access/change and actual participant-flow data
Further research: Propose follow-up research on allocation and period-specific population relationships; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Crossover allocation sequence, generation/concealment and actual procedures requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Crossover allocation sequence, generation/concealment and actual procedures to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M08 §8.2.2, M15 §15.3.1; custom application

Related sources S01

N07 · Masking and MRI assessment

Current findings: Preserve the double-blind design.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Actual masking of participants/researchers, MRI measurement/readers and analysts, maintenance/unmasking and imaging/region-of-interest standards are unverified. Content review remains incomplete.
Reason for missing information: Actual masking of participants/researchers, MRI measurement/readers and analysts, maintenance/unmasking and imaging/region-of-interest standards are unverified.
Required materials and conditions: Role-specific masking, measurement/image assessment and analysis procedures
Materials to obtain first: Role-specific masking and MRI measurement/reading/analysis records
Further research: Propose follow-up research on measurement/assessment bias and MRI results; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Role-specific masking, measurement/image assessment and analysis procedures requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Role-specific masking, measurement/image assessment and analysis procedures to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design

Related sources S01

N08 · MRI-PDFF and the 12-week measure

Current findings: The original account describes MRI-PDFF intrahepatic lipid as an imaging surrogate and the 12-week primary outcome. It is distinct from cirrhosis, hospitalization and death.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Measurement/regions of interest, actual visits/repeats, baseline/final/period-specific comparison definitions and arm-specific observations are unverified. Content review remains incomplete.
Reason for missing information: Measurement/regions of interest, actual visits/repeats, baseline/final/period-specific comparison definitions and arm-specific observations are unverified.
Required materials and conditions: Definition, units/measurement and timing of the intrahepatic-lipid measure
Materials to obtain first: Original MRI measure, measurements/repeats and period/observation data
Further research: Propose follow-up research distinguishing imaging measures from other outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Definition, units/measurement and timing of the intrahepatic-lipid measure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Definition, units/measurement and timing of the intrahepatic-lipid measure to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M03 §3.2.4; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary

Related sources S01

N09 · Quercetin-period baseline and final values

Current findings: Preserve quercetin-period 11.5%±6.4 to 9.6%±5.8 exactly. The manuscript’s approximate −1.9 percentage points is an existing historical reported/explanatory value, not a calculation performed now.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Arm/sequence, period-baseline/final observations, the type of ± quantity, models/adjustment and individual values are unverified. Do not calculate new changes, response rates or CIs. Content review remains incomplete.
Reason for missing information: Arm/sequence, period-baseline/final observations, the type of ± quantity, models/adjustment and individual values are unverified. Do not calculate new changes, response rates or CIs.
Required materials and conditions: Periods/populations, dispersion and distinction from change in original MRI values
Materials to obtain first: Period-specific baseline/final, dispersion/observation and original-estimate data
Further research: Propose follow-up research on final values/change and period-specific analysis definitions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Periods/populations, dispersion and distinction from change in original MRI values requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Periods/populations, dispersion and distinction from change in original MRI values to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N10 · Placebo change and units

Current findings: Preserve the original placebo-period change of −0.1%±2.6. Keep the Korean concise summary’s %p wording in the whole original summary; do not arbitrarily correct units or create new final values/between-treatment differences.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Placebo-period baseline/final values, exact change definitions/units, the type of ± quantity, observed denominators/models and period matching are unverified. Content review remains incomplete.
Reason for missing information: Placebo-period baseline/final values, exact change definitions/units, the type of ± quantity, observed denominators/models and period matching are unverified.
Required materials and conditions: Placebo-period change/final values, original units and estimands
Materials to obtain first: Original placebo-period values/units, change/observations and analysis data
Further research: Propose follow-up research distinguishing original estimands/units and comparison relationships; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Placebo-period change/final values, original units and estimands requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Placebo-period change/final values, original units and estimands to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N11 · P=.013 and adjusted P=.028

Current findings: Preserve between-treatment P=.013 and multiplicity-adjusted P=.028 exactly. Do not calculate/certify new risk ratios/response rates, exact effects/CIs or clinical success.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Period/sequence, within-person correlation, adjustment/multiplicity methods, test lists and original estimates/outputs are unread. Content review remains incomplete.
Reason for missing information: Period/sequence, within-person correlation, adjustment/multiplicity methods, test lists and original estimates/outputs are unread.
Required materials and conditions: Original test for the selected comparison, multiplicity/models and precision
Materials to obtain first: Original analyses/SAP, models, multiplicity and exact-output data
Further research: Propose follow-up research on tests/multiplicity and uncertainty; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original test for the selected comparison, multiplicity/models and precision requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Original test for the selected comparison, multiplicity/models and precision to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N12 · Between-treatment CI and historical checking scope

Current findings: Preserve the original statement that a between-treatment 95% CI was absent within the historically checked abstract/public-result-table scope. Only the preserved summary is read now; do not extend this to absence from the whole paper.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Original estimates/outputs, whole text/supplements and current CI/analysis data are unread. Do not create a new CI from original ± values, P values or sample sizes. Content review remains incomplete.
Reason for missing information: Original estimates/outputs, whole text/supplements and current CI/analysis data are unread. Do not create a new CI from original ± values, P values or sample sizes.
Required materials and conditions: Precision and abstract/public-table checking versus current reading scope
Materials to obtain first: Original paper/supplements, exact outputs and between-treatment CI data
Further research: Propose update research distinguishing precision data from materials actually read; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Precision and abstract/public-table checking versus current reading scope requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Precision and abstract/public-table checking versus current reading scope to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N13 · Prespecified important MRI threshold

Current findings: Preserve the original statement that no minimum clinically important MRI-PDFF reduction threshold was declared. Do not promote statistical positivity to long-term clinical outcomes or confirmatory success.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Prespecified criteria, power/plans, correspondence to clinical measures and exact estimates/CIs are unverified. Content review remains incomplete.
Reason for missing information: Prespecified criteria, power/plans, correspondence to clinical measures and exact estimates/CIs are unverified.
Required materials and conditions: Prespecified minimum clinically important difference and interpretation/success definitions
Materials to obtain first: Prespecified plans, important differences/power and clinical-correspondence data
Further research: Propose research distinguishing statistical results from important differences/clinical meaning; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Prespecified minimum clinically important difference and interpretation/success definitions requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Prespecified minimum clinically important difference and interpretation/success definitions to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary

Related sources S01

N14 · 41 to 36: completion and analysis

Current findings: Preserve 41 randomized and 36 completed exactly. Do not calculate/declare new missing counts/rates, summed periods or a completer-only ITT population.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Sequence/period-specific completion, endpoint observations, withdrawal/missingness reasons, actual analysis populations and sensitivity analyses are unverified. Content review remains incomplete.
Reason for missing information: Sequence/period-specific completion, endpoint observations, withdrawal/missingness reasons, actual analysis populations and sensitivity analyses are unverified.
Required materials and conditions: Randomized/completed participants, period-specific observations/analysis and missingness
Materials to obtain first: Sequence/period-specific flow, observation/missingness and analysis data
Further research: Propose follow-up research on selected populations and missing-data assumptions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Randomized/completed participants, period-specific observations/analysis and missingness requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Randomized/completed participants, period-specific observations/analysis and missingness to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application

Related sources S01

N15 · ITT and crossover model

Current findings: Preserve the original account that ITT results were reported. Do not fill this in as verified MRI observations/denominators in every period for all 41 participants or a particular imputation model.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. MRI ITT denominators, within-person correlation, period/sequence, missing-data models, sensitivity analyses and actual original analyses are unread. Content review remains incomplete.
Reason for missing information: MRI ITT denominators, within-person correlation, period/sequence, missing-data models, sensitivity analyses and actual original analyses are unread.
Required materials and conditions: Actual ITT/allocation and period/sequence/within-person comparison definitions
Materials to obtain first: ITT/crossover models and period-specific denominator/missingness/sensitivity data
Further research: Propose follow-up research on allocation/period, missing-data assumptions and estimation; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual ITT/allocation and period/sequence/within-person comparison definitions requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Actual ITT/allocation and period/sequence/within-person comparison definitions to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M15 §15.3.1–15.3.3; custom application

Related sources S01

N16 · Washout, carryover and period effects

Current findings: Preserve the original design of crossover after a 4-week washout. Do not treat the two periods as different participants or independent replication.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Return to baseline, carryover/sequence/period effects, tests/interactions, actual analyses and exposure adherence are unverified. Content review remains incomplete.
Reason for missing information: Return to baseline, carryover/sequence/period effects, tests/interactions, actual analyses and exposure adherence are unverified.
Required materials and conditions: Carryover/sequence, period-specific baselines and analytical handling
Materials to obtain first: Period baselines, carryover/sequence handling and model/exposure data
Further research: Propose research distinguishing carryover/period effects from same-participant outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Carryover/sequence, period-specific baselines and analytical handling requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Carryover/sequence, period-specific baselines and analytical handling to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N17 · Weight change and correlation

Current findings: Preserve the original weight change of −1.5±2.6 kg during quercetin versus −0.2±1.8 kg during placebo and its correlation with liver-fat reduction. Direct hepatic and weight-mediated effects were not separated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Correlation estimates, timing/populations, models/mediation analyses, concomitant activity/diet and original individual data are unverified. Do not calculate a new direct hepatic effect. Content review remains incomplete.
Reason for missing information: Correlation estimates, timing/populations, models/mediation analyses, concomitant activity/diet and original individual data are unverified. Do not calculate a new direct hepatic effect.
Required materials and conditions: Separate weight/liver-fat measures and causal/mediation relationships
Materials to obtain first: Individual weight/fat trajectories, correlation/mediation models and concomitant exposure data
Further research: Propose follow-up research distinguishing weight/exposure from result attribution; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Separate weight/liver-fat measures and causal/mediation relationships requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Separate weight/liver-fat measures and causal/mediation relationships to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.4; custom extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design

Related sources S01

N18 · Null liver-enzyme and other secondary outcomes

Current findings: Preserve the original account that liver enzymes and other secondary endpoints were not significant. Do not reuse MRI positivity as benefits for liver enzymes or every clinical outcome.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Each measure/time point, denominator, value/estimate/CI, multiplicity and hierarchy are unverified. Do not turn nonsignificance into an exactly zero effect or equivalence. Content review remains incomplete.
Reason for missing information: Each measure/time point, denominator, value/estimate/CI, multiplicity and hierarchy are unverified. Do not turn nonsignificance into an exactly zero effect or equivalence.
Required materials and conditions: Definitions/hierarchy of other endpoints, original results and the selected measure
Materials to obtain first: Original plans/measurements, values/estimates and CIs for each secondary measure
Further research: Propose research on other measures, discordance and uncertainty; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Definitions/hierarchy of other endpoints, original results and the selected measure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Definitions/hierarchy of other endpoints, original results and the selected measure to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M04 §4.6.3; custom application; M15 §15.3.1–15.3.3; custom application

Related sources S01

N19 · Concomitant exposure, adherence and subsequent care

Current findings: Preserve the original scope of the specific quercetin/placebo crossover.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Diet/activity, weight management, drugs/supplements, actual intake/stopping/crossover and exposure in each period are unverified. Do not create new weight/diet/exercise, treatment or intake instructions. Content review remains incomplete.
Reason for missing information: Diet/activity, weight management, drugs/supplements, actual intake/stopping/crossover and exposure in each period are unverified. Do not create new weight/diet/exercise, treatment or intake instructions.
Required materials and conditions: Arm/period-specific activity/diet, drugs/products and actual exposure
Materials to obtain first: Period-specific concomitant exposure, adherence/changes and weight/management records
Further research: Propose research on concomitant exposure and result attribution; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Arm/period-specific activity/diet, drugs/products and actual exposure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Arm/period-specific activity/diet, drugs/products and actual exposure to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

Related sources S01

N20 · ChiCTR and prespecified plans

Current findings: Preserve the original registration-field value ChiCTR2100047904. A registration number alone does not verify prespecification, original plans or CIs/criteria now.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Registration history, protocol/SAP, recruitment/measurement/analysis timing, multiplicity and amendments are unread. Content review remains incomplete.
Reason for missing information: Registration history, protocol/SAP, recruitment/measurement/analysis timing, multiplicity and amendments are unread.
Required materials and conditions: Registration identity, plans/changes and correspondence to reports
Materials to obtain first: Registration history, protocol/SAP and report/amendment data
Further research: Propose research connecting prespecified plans to result reporting; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Registration identity, plans/changes and correspondence to reports requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Registration identity, plans/changes and correspondence to reports to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N21 · Funding-agency names and unverified scope

Current findings: Preserve the original funding/Korean-English account that a separate joint funding-agency name was not identified in the public text. Do not turn this into no funding or independence certification.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Actual providers/contracts, research/analysis/writing/publication roles and complete disclosures are unread now. Content review remains incomplete.
Reason for missing information: Actual providers/contracts, research/analysis/writing/publication roles and complete disclosures are unread now.
Required materials and conditions: Funders, roles and the scope of the public text
Materials to obtain first: Funding contracts, providers/roles and original disclosures for each support item
Further research: Propose update research on historical checking scope and current materials; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Funders, roles and the scope of the public text requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Funders, roles and the scope of the public text to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N22 · Manufacturer, product and analysis disclosures

Current findings: The original account states that commercial-manufacturer funding, free products and outsourced analysis were not disclosed in the public text. Do not convert non-disclosure into no support or verification of all independence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Manufacturing/supply, individual support, writing/publication fees and actual complete original disclosures are unread. Content review remains incomplete.
Reason for missing information: Manufacturing/supply, individual support, writing/publication fees and actual complete original disclosures are unread.
Required materials and conditions: Individual records of commercial funding/products and analysis/writing/publication support
Materials to obtain first: Product/support, manufacturing/contribution and original writing/publication disclosures
Further research: Propose research distinguishing gaps in individual disclosures/support; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Individual records of commercial funding/products and analysis/writing/publication support requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Individual records of commercial funding/products and analysis/writing/publication support to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

Related sources S01

N23 · Institutional affiliations and COI declarations

Current findings: Preserve the original account of Army Medical University/Xinqiao Hospital affiliations and a no-competing-interests declaration. Institutional affiliation does not certify funding or current independence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Staff/contributions, timing of relationships/employment, equity/other COIs and detailed disclosures are unread. Content review remains incomplete.
Reason for missing information: Staff/contributions, timing of relationships/employment, equity/other COIs and detailed disclosures are unread.
Required materials and conditions: Distinguish author affiliations/employment from contributions/interests
Materials to obtain first: Author-specific affiliation/employment, contribution and original COI disclosures
Further research: Propose research on declarations and author/institutional roles; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Distinguish author affiliations/employment from contributions/interests requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Distinguish author affiliations/employment from contributions/interests to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N24 · Safety measures and rare harms

Current findings: Preserve the original account that significant between-treatment differences in routine blood and other safety measures and intervention-related adverse events were not reported, together with the limitation that 41 participants are too few to evaluate rare harms.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Arm/period-specific harm denominators/events, collection/stopping/relatedness/missingness and long-term/vulnerable populations are unverified. Do not turn non-reporting/nonsignificance into zero harms or safety certification. Content review remains incomplete.
Reason for missing information: Arm/period-specific harm denominators/events, collection/stopping/relatedness/missingness and long-term/vulnerable populations are unverified. Do not turn non-reporting/nonsignificance into zero harms or safety certification.
Required materials and conditions: Harm collection/definitions, populations/periods and original reporting scope
Materials to obtain first: Harm collection, arm-specific denominators/events and stopping/follow-up data
Further research: Propose research on harm-reporting scope and rare/long-term outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Harm collection/definitions, populations/periods and original reporting scope requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Harm collection/definitions, populations/periods and original reporting scope to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Supplement gaps in safety materials for the selected subclaim. Do not judge safety from MRI/clinical results or parent safety wording, or create harm-incidence estimates/new use instructions.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are custom design; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4, M04 §4.6.3; custom application; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4; custom application

Related sources S01

N25 · Relationships within the same trial across periods/reports

Current findings: Do not sum the single Li 2024/ChiCTR trial, 41 participants/36 completers, two periods/measurement times or MRI/weight/liver enzymes/sibling sheets as new independent trials/participants. Original R1/I2 are historical axes.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. External correspondence of same-participant periods/endpoints, unique populations/follow-up reports and independent replication under matching conditions has not been checked. Do not invent follow-up reports. Content review remains incomplete.
Reason for missing information: External correspondence of same-participant periods/endpoints, unique populations/follow-up reports and independent replication under matching conditions has not been checked. Do not invent follow-up reports.
Required materials and conditions: Distinguish reports/trials/participants, crossover/measures and independent replication
Materials to obtain first: Trial/registration/participant, period/endpoint/report relationships and separate evidence
Further research: Propose research on same-data/period relationships and separate replication; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Distinguish reports/trials/participants, crossover/measures and independent replication requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Distinguish reports/trials/participants, crossover/measures and independent replication to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N26 · Clinical outcomes and other formulations/durations

Current findings: MRI positivity is not evidence of improved cirrhosis, hospitalization or death. Do not extend the specific 500 mg/12-week result to every polyphenol or other formulations/populations/long-term effects.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical outcomes, post-treatment durability, other doses/populations/periods and harms are unverified. Do not create treatment/intake methods. Content review remains incomplete.
Reason for missing information: Direct clinical outcomes, post-treatment durability, other doses/populations/periods and harms are unverified. Do not create treatment/intake methods.
Required materials and conditions: Distinguish selected MRI results from actual clinical outcomes/outside populations
Materials to obtain first: Additional clinical-endpoint, formulation/population and long-term follow-up materials
Further research: Propose research distinguishing imaging from clinical outcomes and selected conditions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Distinguish selected MRI results from actual clinical outcomes/outside populations requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Distinguish selected MRI results from actual clinical outcomes/outside populations to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4; custom extension boundary; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design

Related sources S01

N27 · Original axes, Korean/English text, dates and corrections

Current findings: The whole preserved summary retains subclaim C/note, parent C with 54 points/Good, B/S/R1/I2/E+/B1, unrecorded precision, three false flags, empty override reasons, Korean/English text, 2026-08-26 and empty corrections/deliberation.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Historical cross-check/abstract/public-table/full-text checking accounts are not current external reading/review or newly fulfilled conditions. Do not fill absent subclaim score/status/axes or absent parent classification keys. Content review remains incomplete.
Reason for missing information: Historical cross-check/abstract/public-table/full-text checking accounts are not current external reading/review or newly fulfilled conditions. Do not fill absent subclaim score/status/axes or absent parent classification keys.
Required materials and conditions: Distinguish subclaim/parent values, original evidence date/corrections and history
Materials to obtain first: Original verdict/corrections, amended manuscripts and human comments
Further research: Propose update research on source-material changes and production versions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Distinguish subclaim/parent values, original evidence date/corrections and history requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Distinguish subclaim/parent values, original evidence date/corrections and history to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

Related sources S01

N28 · Summary reading and externally unread materials

Current findings: The preserved summary was read for production, and the Li 2024/PMID 39032786 citation/URL is linked. Paper/registration/protocol/SAP/disclosures remain unread, with no access attempted.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Original URLs/registration and historical accounts do not raise current acquisition/reading/review status; external links/clicks have not been checked. Content review remains incomplete.
Reason for missing information: Original URLs/registration and historical accounts do not raise current acquisition/reading/review status; external links/clicks have not been checked.
Required materials and conditions: Actual reading for each material, citations/URLs and gaps in additional materials
Materials to obtain first: Original reports/registration/plans/disclosures and human comments
Further research: Propose scoped update research based on materials actually acquired; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual reading for each material, citations/URLs and gaps in additional materials requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Actual reading for each material, citations/URLs and gaps in additional materials to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01